The first three BTK inhibitors (BTKi) covalently bind to cysteine C481 of the BTK protein and irreversibly inhibit BTK but are dogged by off-target binding – leading to adverse events – and ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström MacroglobulinemiaFirst-in-class ...

Rilzabrutinib has been specifically designed to be highly selective for the BTK protein and avoid off-target side effects. The result is a boost for Sanofi’s blockbuster aspirations for the BTK ...

BeiGene’s third asset in CLL, a BTK protein degrader coded BGB-16673, could read out potentially registrational phase 2 data in 2026. Again, going bold, BeiGene plans to start a phase 3 head-to ...

The Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation have awarded Dr. Owen Witte(Link is external) (Link opens in new window) with the twelfth ...

Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in ...

Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type ...

When Jennifer Woyach, MD, started as a resident and fellow two decades ago, patients with chronic lymphocytic leukemia (CLL) ...

Leerink analyst Faisal A. Khurshid initiated coverage of Nurix Therapeutics (NRIX) with a Market Perform rating and $16 price target The firm ...

Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B ...